nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—HTR1E—female gonad—cervical cancer	0.0198	0.0765	CbGeAlD
Methysergide—Heartburn—Topotecan—cervical cancer	0.0192	0.114	CcSEcCtD
Methysergide—Pleural effusion—Topotecan—cervical cancer	0.0172	0.103	CcSEcCtD
Methysergide—SIGMAR1—uterine cervix—cervical cancer	0.0124	0.0479	CbGeAlD
Methysergide—HTR2B—uterine cervix—cervical cancer	0.0124	0.0478	CbGeAlD
Methysergide—SIGMAR1—decidua—cervical cancer	0.0118	0.0456	CbGeAlD
Methysergide—HTR2B—decidua—cervical cancer	0.0118	0.0455	CbGeAlD
Methysergide—SIGMAR1—endometrium—cervical cancer	0.0112	0.0433	CbGeAlD
Methysergide—HTR2B—endometrium—cervical cancer	0.0112	0.0432	CbGeAlD
Methysergide—SIGMAR1—mammalian vulva—cervical cancer	0.0108	0.0419	CbGeAlD
Methysergide—HTR7—epithelium—cervical cancer	0.0107	0.0413	CbGeAlD
Methysergide—HTR1A—renal system—cervical cancer	0.0104	0.0401	CbGeAlD
Methysergide—SIGMAR1—uterus—cervical cancer	0.0103	0.0399	CbGeAlD
Methysergide—HTR2B—uterus—cervical cancer	0.0103	0.0398	CbGeAlD
Methysergide—HTR1B—female reproductive system—cervical cancer	0.0103	0.0398	CbGeAlD
Methysergide—HTR1D—female reproductive system—cervical cancer	0.00997	0.0385	CbGeAlD
Methysergide—HTR7—renal system—cervical cancer	0.00991	0.0383	CbGeAlD
Methysergide—HTR2C—female reproductive system—cervical cancer	0.00987	0.0381	CbGeAlD
Methysergide—HTR2B—female reproductive system—cervical cancer	0.00927	0.0358	CbGeAlD
Methysergide—SIGMAR1—female gonad—cervical cancer	0.00845	0.0327	CbGeAlD
Methysergide—SIGMAR1—vagina—cervical cancer	0.0084	0.0325	CbGeAlD
Methysergide—HTR2B—vagina—cervical cancer	0.00838	0.0324	CbGeAlD
Methysergide—HTR7—female reproductive system—cervical cancer	0.00794	0.0307	CbGeAlD
Methysergide—Neutropenia—Topotecan—cervical cancer	0.00774	0.0462	CcSEcCtD
Methysergide—Weight increased—Topotecan—cervical cancer	0.00753	0.045	CcSEcCtD
Methysergide—HTR2A—epithelium—cervical cancer	0.00666	0.0257	CbGeAlD
Methysergide—HTR2A—renal system—cervical cancer	0.00618	0.0239	CbGeAlD
Methysergide—Alopecia—Topotecan—cervical cancer	0.00585	0.035	CcSEcCtD
Methysergide—Back pain—Topotecan—cervical cancer	0.00558	0.0333	CcSEcCtD
Methysergide—SIGMAR1—lymph node—cervical cancer	0.00544	0.021	CbGeAlD
Methysergide—HTR2B—lymph node—cervical cancer	0.00542	0.021	CbGeAlD
Methysergide—Ill-defined disorder—Topotecan—cervical cancer	0.00535	0.032	CcSEcCtD
Methysergide—Malaise—Topotecan—cervical cancer	0.0052	0.0311	CcSEcCtD
Methysergide—HTR2A—female reproductive system—cervical cancer	0.00495	0.0191	CbGeAlD
Methysergide—Arthralgia—Topotecan—cervical cancer	0.00491	0.0293	CcSEcCtD
Methysergide—Chest pain—Topotecan—cervical cancer	0.00491	0.0293	CcSEcCtD
Methysergide—Myalgia—Topotecan—cervical cancer	0.00491	0.0293	CcSEcCtD
Methysergide—Discomfort—Topotecan—cervical cancer	0.00485	0.029	CcSEcCtD
Methysergide—Thrombocytopenia—Topotecan—cervical cancer	0.00461	0.0275	CcSEcCtD
Methysergide—HTR2A—vagina—cervical cancer	0.00448	0.0173	CbGeAlD
Methysergide—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00429	0.0256	CcSEcCtD
Methysergide—Paraesthesia—Topotecan—cervical cancer	0.00422	0.0252	CcSEcCtD
Methysergide—Dyspnoea—Topotecan—cervical cancer	0.00419	0.0251	CcSEcCtD
Methysergide—Dyspepsia—Topotecan—cervical cancer	0.00414	0.0247	CcSEcCtD
Methysergide—Gastrointestinal disorder—Topotecan—cervical cancer	0.00406	0.0243	CcSEcCtD
Methysergide—Fatigue—Topotecan—cervical cancer	0.00406	0.0242	CcSEcCtD
Methysergide—Pain—Topotecan—cervical cancer	0.00402	0.024	CcSEcCtD
Methysergide—Constipation—Topotecan—cervical cancer	0.00402	0.024	CcSEcCtD
Methysergide—Feeling abnormal—Topotecan—cervical cancer	0.00388	0.0232	CcSEcCtD
Methysergide—Gastrointestinal pain—Topotecan—cervical cancer	0.00385	0.023	CcSEcCtD
Methysergide—Abdominal pain—Topotecan—cervical cancer	0.00372	0.0222	CcSEcCtD
Methysergide—Body temperature increased—Topotecan—cervical cancer	0.00372	0.0222	CcSEcCtD
Methysergide—Asthenia—Topotecan—cervical cancer	0.00338	0.0202	CcSEcCtD
Methysergide—Diarrhoea—Topotecan—cervical cancer	0.00322	0.0192	CcSEcCtD
Methysergide—Dizziness—Topotecan—cervical cancer	0.00311	0.0186	CcSEcCtD
Methysergide—HTR1E—GPCR ligand binding—WNT5A—cervical cancer	0.0031	0.00539	CbGpPWpGaD
Methysergide—HTR2A—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.003	0.00523	CbGpPWpGaD
Methysergide—Vomiting—Topotecan—cervical cancer	0.00299	0.0179	CcSEcCtD
Methysergide—Rash—Topotecan—cervical cancer	0.00297	0.0177	CcSEcCtD
Methysergide—Dermatitis—Topotecan—cervical cancer	0.00296	0.0177	CcSEcCtD
Methysergide—HTR1E—GPCR downstream signaling—TAAR6—cervical cancer	0.00296	0.00515	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—TAAR6—cervical cancer	0.00285	0.00496	CbGpPWpGaD
Methysergide—Nausea—Topotecan—cervical cancer	0.00279	0.0167	CcSEcCtD
Methysergide—HTR6—GPCR ligand binding—WNT2—cervical cancer	0.00279	0.00486	CbGpPWpGaD
Methysergide—HTR7—GPCR ligand binding—WNT2—cervical cancer	0.00279	0.00486	CbGpPWpGaD
Methysergide—HTR1D—GPCR ligand binding—WNT2—cervical cancer	0.00277	0.00483	CbGpPWpGaD
Methysergide—HTR1B—GPCR ligand binding—WNT2—cervical cancer	0.00271	0.00472	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—TAAR6—cervical cancer	0.00268	0.00468	CbGpPWpGaD
Methysergide—HTR1A—GPCR ligand binding—TAAR6—cervical cancer	0.00265	0.00461	CbGpPWpGaD
Methysergide—HTR2C—GPCR ligand binding—TAAR6—cervical cancer	0.00263	0.00459	CbGpPWpGaD
Methysergide—HTR2B—GPCR ligand binding—WNT2—cervical cancer	0.00255	0.00444	CbGpPWpGaD
Methysergide—HTR2A—GPCR ligand binding—TAAR6—cervical cancer	0.00229	0.00398	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—WNT2—cervical cancer	0.00222	0.00387	CbGpPWpGaD
Methysergide—HTR1F—GPCR downstream signaling—AKAP13—cervical cancer	0.00215	0.00374	CbGpPWpGaD
Methysergide—HTR6—GPCR ligand binding—WNT5A—cervical cancer	0.00211	0.00369	CbGpPWpGaD
Methysergide—HTR7—GPCR ligand binding—WNT5A—cervical cancer	0.00211	0.00368	CbGpPWpGaD
Methysergide—HTR1D—GPCR ligand binding—WNT5A—cervical cancer	0.0021	0.00366	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—WNT2—cervical cancer	0.0021	0.00365	CbGpPWpGaD
Methysergide—HTR1A—GPCR ligand binding—WNT2—cervical cancer	0.00207	0.0036	CbGpPWpGaD
Methysergide—HTR1A—SIDS Susceptibility Pathways—HES1—cervical cancer	0.00206	0.0036	CbGpPWpGaD
Methysergide—HTR1B—GPCR ligand binding—WNT5A—cervical cancer	0.00205	0.00358	CbGpPWpGaD
Methysergide—HTR2C—GPCR ligand binding—WNT2—cervical cancer	0.00205	0.00358	CbGpPWpGaD
Methysergide—HTR1E—GPCR downstream signaling—AKAP13—cervical cancer	0.00203	0.00353	CbGpPWpGaD
Methysergide—HTR6—GPCR downstream signaling—TAAR6—cervical cancer	0.00202	0.00352	CbGpPWpGaD
Methysergide—HTR7—GPCR downstream signaling—TAAR6—cervical cancer	0.00202	0.00352	CbGpPWpGaD
Methysergide—HTR1D—GPCR downstream signaling—TAAR6—cervical cancer	0.002	0.00349	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—TAAR6—cervical cancer	0.00196	0.00342	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—AKAP13—cervical cancer	0.00195	0.0034	CbGpPWpGaD
Methysergide—HTR2B—GPCR ligand binding—WNT5A—cervical cancer	0.00193	0.00336	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—TAAR6—cervical cancer	0.00184	0.00321	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—AKAP13—cervical cancer	0.00184	0.00321	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—TAAR6—cervical cancer	0.00183	0.0032	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—TAAR6—cervical cancer	0.00183	0.00319	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—TAAR6—cervical cancer	0.00182	0.00317	CbGpPWpGaD
Methysergide—HTR2A—GPCR ligand binding—WNT2—cervical cancer	0.00178	0.00311	CbGpPWpGaD
Methysergide—HTR2A—SIDS Susceptibility Pathways—HES1—cervical cancer	0.00178	0.00311	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—TAAR6—cervical cancer	0.00178	0.00311	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—WNT5A—cervical cancer	0.00168	0.00293	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TAAR6—cervical cancer	0.00168	0.00293	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—TAAR6—cervical cancer	0.00167	0.00292	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—WNT5A—cervical cancer	0.00159	0.00277	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TAAR6—cervical cancer	0.00159	0.00276	CbGpPWpGaD
Methysergide—HTR1A—GPCR ligand binding—WNT5A—cervical cancer	0.00157	0.00273	CbGpPWpGaD
Methysergide—HTR2C—GPCR ligand binding—WNT5A—cervical cancer	0.00156	0.00271	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—TAAR6—cervical cancer	0.0015	0.00261	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—TAAR6—cervical cancer	0.00149	0.00259	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—WNT2—cervical cancer	0.00143	0.0025	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—WNT2—cervical cancer	0.00143	0.00249	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—WNT2—cervical cancer	0.00142	0.00248	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—WNT2—cervical cancer	0.00139	0.00242	CbGpPWpGaD
Methysergide—HTR6—GPCR downstream signaling—AKAP13—cervical cancer	0.00138	0.00241	CbGpPWpGaD
Methysergide—HTR7—GPCR downstream signaling—AKAP13—cervical cancer	0.00138	0.00241	CbGpPWpGaD
Methysergide—HTR1D—GPCR downstream signaling—AKAP13—cervical cancer	0.00137	0.00239	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—TAAR6—cervical cancer	0.00136	0.00237	CbGpPWpGaD
Methysergide—HTR2A—GPCR ligand binding—WNT5A—cervical cancer	0.00135	0.00236	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—TAAR6—cervical cancer	0.00135	0.00235	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—AKAP13—cervical cancer	0.00135	0.00234	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—WNT2—cervical cancer	0.00131	0.00229	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—WNT2—cervical cancer	0.00131	0.00228	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—TAAR6—cervical cancer	0.00129	0.00225	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—AKAP13—cervical cancer	0.00126	0.0022	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—AKAP13—cervical cancer	0.00126	0.00219	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—AKAP13—cervical cancer	0.00126	0.00219	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—AKAP13—cervical cancer	0.00125	0.00217	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—WNT2—cervical cancer	0.00124	0.00216	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—AKAP13—cervical cancer	0.00122	0.00213	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—TAAR6—cervical cancer	0.00117	0.00204	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—AKAP13—cervical cancer	0.00115	0.00201	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—AKAP13—cervical cancer	0.00115	0.002	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—AKAP13—cervical cancer	0.00109	0.00189	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—WNT5A—cervical cancer	0.00109	0.00189	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—WNT5A—cervical cancer	0.00108	0.00189	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TAAR6—cervical cancer	0.00108	0.00189	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TAAR6—cervical cancer	0.00108	0.00189	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—WNT5A—cervical cancer	0.00108	0.00188	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TAAR6—cervical cancer	0.00108	0.00187	CbGpPWpGaD
Methysergide—HTR1A—SIDS Susceptibility Pathways—CASP3—cervical cancer	0.00107	0.00187	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—WNT2—cervical cancer	0.00106	0.00185	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—WNT5A—cervical cancer	0.00105	0.00184	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—WNT2—cervical cancer	0.00105	0.00184	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TAAR6—cervical cancer	0.00105	0.00183	CbGpPWpGaD
Methysergide—HTR1A—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	0.00104	0.0018	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—AKAP13—cervical cancer	0.00102	0.00179	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—AKAP13—cervical cancer	0.00102	0.00178	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—WNT5A—cervical cancer	0.000995	0.00173	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—WNT5A—cervical cancer	0.00099	0.00173	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TAAR6—cervical cancer	0.000989	0.00172	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—WNT5A—cervical cancer	0.000938	0.00164	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—AKAP13—cervical cancer	0.000931	0.00162	CbGpPWpGaD
Methysergide—HTR2A—SIDS Susceptibility Pathways—CASP3—cervical cancer	0.000928	0.00162	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—AKAP13—cervical cancer	0.000926	0.00161	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—WNT2—cervical cancer	0.000916	0.0016	CbGpPWpGaD
Methysergide—HTR2A—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	0.000895	0.00156	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—AKAP13—cervical cancer	0.000885	0.00154	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—WNT2—cervical cancer	0.000846	0.00147	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—WNT2—cervical cancer	0.000845	0.00147	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—WNT2—cervical cancer	0.000839	0.00146	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—WNT2—cervical cancer	0.000822	0.00143	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—AKAP13—cervical cancer	0.000804	0.0014	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—WNT5A—cervical cancer	0.000803	0.0014	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TAAR6—cervical cancer	0.000802	0.0014	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—WNT5A—cervical cancer	0.000799	0.00139	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TAAR6—cervical cancer	0.000798	0.00139	CbGpPWpGaD
Methysergide—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.000783	0.00136	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—WNT2—cervical cancer	0.000772	0.00135	CbGpPWpGaD
Methysergide—HTR7—Circadian rythm related genes—TP53—cervical cancer	0.000759	0.00132	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—AKAP13—cervical cancer	0.000743	0.00129	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—AKAP13—cervical cancer	0.000742	0.00129	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—AKAP13—cervical cancer	0.000737	0.00128	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—AKAP13—cervical cancer	0.000722	0.00126	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—NOTCH2—cervical cancer	0.000698	0.00122	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—WNT5A—cervical cancer	0.000694	0.00121	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TAAR6—cervical cancer	0.000693	0.00121	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—AKAP13—cervical cancer	0.000678	0.00118	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—NOTCH2—cervical cancer	0.000659	0.00115	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—WNT5A—cervical cancer	0.000641	0.00112	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—WNT5A—cervical cancer	0.00064	0.00112	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—WNT5A—cervical cancer	0.000636	0.00111	CbGpPWpGaD
Methysergide—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.000631	0.0011	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—WNT2—cervical cancer	0.000626	0.00109	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—WNT5A—cervical cancer	0.000623	0.00109	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—WNT2—cervical cancer	0.000623	0.00109	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—WNT5A—cervical cancer	0.000585	0.00102	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—HES1—cervical cancer	0.000572	0.000998	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AKAP13—cervical cancer	0.00055	0.000958	CbGpPWpGaD
Methysergide—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.000548	0.000956	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AKAP13—cervical cancer	0.000547	0.000953	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—WNT2—cervical cancer	0.000541	0.000943	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—HES1—cervical cancer	0.00054	0.000941	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TERT—cervical cancer	0.000502	0.000874	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AKAP13—cervical cancer	0.000475	0.000828	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—WNT5A—cervical cancer	0.000474	0.000827	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TERT—cervical cancer	0.000473	0.000825	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—WNT5A—cervical cancer	0.000472	0.000823	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—FGFR3—cervical cancer	0.00046	0.000802	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NOTCH2—cervical cancer	0.00045	0.000784	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NOTCH2—cervical cancer	0.000449	0.000783	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NOTCH2—cervical cancer	0.000446	0.000778	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NOTCH2—cervical cancer	0.000437	0.000762	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—FGFR3—cervical cancer	0.000434	0.000757	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—NOTCH1—cervical cancer	0.000432	0.000753	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NOTCH2—cervical cancer	0.000411	0.000716	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—WNT5A—cervical cancer	0.00041	0.000714	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—NOTCH1—cervical cancer	0.000408	0.00071	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—EGFR—cervical cancer	0.000385	0.000671	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—HES1—cervical cancer	0.000369	0.000643	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—HES1—cervical cancer	0.000368	0.000642	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—HES1—cervical cancer	0.000366	0.000638	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—EGFR—cervical cancer	0.000363	0.000633	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—HES1—cervical cancer	0.000358	0.000625	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—HES1—cervical cancer	0.000337	0.000587	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NOTCH2—cervical cancer	0.000333	0.00058	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NOTCH2—cervical cancer	0.000331	0.000577	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—MTOR—cervical cancer	0.000324	0.000564	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TERT—cervical cancer	0.000323	0.000563	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TERT—cervical cancer	0.000323	0.000563	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TERT—cervical cancer	0.000321	0.000559	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TERT—cervical cancer	0.000314	0.000547	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—MTOR—cervical cancer	0.000305	0.000532	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—CASP3—cervical cancer	0.000298	0.000519	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—FGFR3—cervical cancer	0.000297	0.000517	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—FGFR3—cervical cancer	0.000296	0.000516	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TERT—cervical cancer	0.000295	0.000514	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—FGFR3—cervical cancer	0.000294	0.000513	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—FGFR3—cervical cancer	0.000288	0.000502	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NOTCH2—cervical cancer	0.000288	0.000501	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—CTNNB1—cervical cancer	0.000287	0.0005	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—CASP3—cervical cancer	0.000281	0.00049	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NOTCH1—cervical cancer	0.000278	0.000485	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NOTCH1—cervical cancer	0.000278	0.000485	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NOTCH1—cervical cancer	0.000276	0.000482	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—HES1—cervical cancer	0.000273	0.000476	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—HES1—cervical cancer	0.000272	0.000473	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—CTNNB1—cervical cancer	0.000271	0.000472	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—FGFR3—cervical cancer	0.000271	0.000472	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NOTCH1—cervical cancer	0.000271	0.000472	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NOTCH1—cervical cancer	0.000254	0.000443	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—STAT3—cervical cancer	0.00025	0.000436	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—EGFR—cervical cancer	0.000248	0.000432	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—EGFR—cervical cancer	0.000248	0.000432	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—EGFR—cervical cancer	0.000246	0.000429	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—EGFR—cervical cancer	0.000241	0.00042	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TERT—cervical cancer	0.000239	0.000417	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TERT—cervical cancer	0.000238	0.000415	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—STAT3—cervical cancer	0.000236	0.000411	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—HES1—cervical cancer	0.000236	0.000411	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—EGFR—cervical cancer	0.000227	0.000396	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—EGFR—cervical cancer	0.000226	0.000395	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—FGFR3—cervical cancer	0.00022	0.000383	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—FGFR3—cervical cancer	0.000218	0.000381	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—EGFR—cervical cancer	0.000215	0.000374	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MTOR—cervical cancer	0.000209	0.000364	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MTOR—cervical cancer	0.000208	0.000363	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MTOR—cervical cancer	0.000207	0.000361	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TERT—cervical cancer	0.000207	0.00036	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NOTCH1—cervical cancer	0.000206	0.000359	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NOTCH1—cervical cancer	0.000205	0.000357	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MTOR—cervical cancer	0.000203	0.000353	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CASP3—cervical cancer	0.000192	0.000334	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CASP3—cervical cancer	0.000192	0.000334	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TP53—cervical cancer	0.000191	0.000333	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MTOR—cervical cancer	0.00019	0.000332	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CASP3—cervical cancer	0.00019	0.000332	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—FGFR3—cervical cancer	0.00019	0.000331	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CASP3—cervical cancer	0.000187	0.000325	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CTNNB1—cervical cancer	0.000185	0.000322	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CTNNB1—cervical cancer	0.000185	0.000322	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—EGFR—cervical cancer	0.000184	0.00032	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CTNNB1—cervical cancer	0.000184	0.00032	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—EGFR—cervical cancer	0.000183	0.000318	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TP53—cervical cancer	0.00018	0.000314	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CTNNB1—cervical cancer	0.00018	0.000313	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NOTCH1—cervical cancer	0.000178	0.00031	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CASP3—cervical cancer	0.000175	0.000305	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CTNNB1—cervical cancer	0.000169	0.000294	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—STAT3—cervical cancer	0.000161	0.000281	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—STAT3—cervical cancer	0.000161	0.000281	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—STAT3—cervical cancer	0.00016	0.000279	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—EGFR—cervical cancer	0.000159	0.000277	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—STAT3—cervical cancer	0.000157	0.000273	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MTOR—cervical cancer	0.000154	0.000269	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MTOR—cervical cancer	0.000154	0.000268	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—STAT3—cervical cancer	0.000147	0.000257	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—EGFR—cervical cancer	0.000147	0.000255	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—EGFR—cervical cancer	0.000146	0.000255	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—EGFR—cervical cancer	0.000145	0.000253	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—EGFR—cervical cancer	0.000142	0.000248	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CASP3—cervical cancer	0.000142	0.000248	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CASP3—cervical cancer	0.000141	0.000246	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CTNNB1—cervical cancer	0.000137	0.000239	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CTNNB1—cervical cancer	0.000136	0.000237	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—EGFR—cervical cancer	0.000134	0.000233	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MTOR—cervical cancer	0.000133	0.000233	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TP53—cervical cancer	0.000123	0.000214	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TP53—cervical cancer	0.000123	0.000214	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CASP3—cervical cancer	0.000123	0.000214	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TP53—cervical cancer	0.000122	0.000213	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TP53—cervical cancer	0.00012	0.000208	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—STAT3—cervical cancer	0.000119	0.000208	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—STAT3—cervical cancer	0.000119	0.000207	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CTNNB1—cervical cancer	0.000118	0.000206	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TP53—cervical cancer	0.000112	0.000196	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EGFR—cervical cancer	0.000108	0.000189	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EGFR—cervical cancer	0.000108	0.000188	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—STAT3—cervical cancer	0.000103	0.00018	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EGFR—cervical cancer	9.37e-05	0.000163	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TP53—cervical cancer	9.11e-05	0.000159	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TP53—cervical cancer	9.06e-05	0.000158	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TP53—cervical cancer	7.87e-05	0.000137	CbGpPWpGaD
